BLACK WEEKSLiekovky −15 % · kity −10 % · ostatné −5 %s kódomDoprava po Nemecku zadarmo od 200 €

Táto stránka bola preložená automaticky a môže obsahovať chyby. Ste rodený hovoriaci? Radi privítame vašu spätnú väzbu a opravy.Poslať spätnú väzbu

The Peptide Desk The Peptide Desk
Tamoxifen (Nolvadex), fotografia produktu

Laboratórna správa

PDF
Testované
Testované
Tamoxifen (Nolvadex) 20mg × 100 Tabs
Laboratórium
Analiza Białek
Dátum
October 2026
Výsledok
20.34 mg per tablet (20 mg label)
Č. objednávky
Heslo

Testované nezávisle, overiteľné heslom priamo v laboratóriu.

PCT & AI

Tamoxifen (Nolvadex)

PCT & AI

Objednávka

Cena za kus - Doprava po Nemecku zadarmo od 200 € počas Black Weeks
  • DHL so sledovaním zásielky
  • Diskrétne balenie

4.6 z 5 na Trustpilote73 hodnotení

V skratke

Tamoxifen (Nolvadex) v číslach

Kľúčové údaje z nášho lexikónu.

Celé heslo v lexikóne
Class
SERMestrogen receptor modulator
Half-life
longseveral days
Use
Oraldaily
Sizes
10 to 20 mg2 sizes in the shop

Znalosti

Všetko o Tamoxifen (Nolvadex)

Podrobné informácie pripravujeme.

Dávkovanie

Načítavajú sa informácie o dávkovaní …

Viac v lexikóne

FAQ

Časté otázky

Zdroje ku každej odpovedi: heslo v lexikóne

Máte ešte otázku?

Napíšte nám, náš tím vám pomôže.

Is tamoxifen approved?

Yes. ChEMBL lists tamoxifen with phase 4 as the highest phase and first approval in 1977. ClinicalTrials.gov lists 685 trials with tamoxifen, almost all on breast cancer, as of 26 October 2026.

How well did tamoxifen prevent gynecomastia in the trial?

114 men received the antiandrogen bicalutamide for 48 weeks, plus placebo, tamoxifen or anastrozole. Gynecomastia developed in 73 percent on placebo, 10 percent on tamoxifen and 51 percent on anastrozole. Breast pain occurred in 39, 6 and 27 percent.

Why was anastrozole weaker?

Anastrozole lowers the production of estrogen, tamoxifen blocks the effect directly at the receptor in the breast gland. In the trial anastrozole did not significantly reduce gynecomastia. A meta-analysis of 9 trials also found no significant benefit for anastrozole.

What does the meta-analysis show?

Nine randomised trials in men on bicalutamide were included. Tamoxifen lowered the risk of gynecomastia and breast pain by 82 percent (relative risk 0.18). Breast radiotherapy lowered the risk of gynecomastia by 52 percent.

Are there data on gynecomastia of unknown cause?

A breast clinic followed 81 men who received tamoxifen over 10 years. In 90.1 percent the gynecomastia resolved completely. There was no control group, so the evidence is limited.

What happened to the hormones?

Testosterone rose in all groups. With tamoxifen free testosterone stayed the same because the binding protein SHBG rose. Adverse events were not more common with tamoxifen than without (35 versus 37 percent).

Porovnania

Porovnanie s ostatnými

Súvisiace

Súvisiace produkty